



Symposium 4: Opportunities of Pharmacoepidemiologists in Precision Medicine in China

Geoffrey Liu



Geoffrey Liu is a medical oncologist, and a research molecular pharmacoepidemiologist. He completed his undergraduate and medical degrees *magna sum laude* from the University of Toronto, and his post-graduate studies at the University of Toronto, Harvard University, and the Harvard School of Public Health. After becoming an Assistant Professor at Harvard, he moved back to his hometown of Toronto, and is now Professor of Medicine, Medical Biophysics, Epidemiology, and at the Institute of Medical Science and the Dalla Lana School of Public Health University of Toronto. Dr. Liu runs an interdisciplinary training program, COMBIEL (Cancer Outcomes, Medicine, Biostatistics, Informatics, Epidemiology and Laboratory), whose trainees have won over 50 research awards. He is a research methods training course co-coordinator for graduate students (Pharmacoepidemiology), for medical residents (Research Methodology) and hematology-oncology fellows (Scientific Thinking). He initiated courses in Pharmacogenomics (2009) and Oncology (2017) at the International Conference for Pharmacoepidemiology (ICPE), and has taught courses at 14 prior ICPE Annual Meetings, ISPE Midyear meetings, and ACPE meetings. He co-hosted the 2018 ISPE Mid-Year Meeting in Toronto, Canada, and became Fellow of ISPE (FISPE) in 2017.

Meng Zhu



Mr Meng is a University Lecturer from Nanjing Medical University. He received his MD and PhD degrees from the Nanjing Medical University, and research experience in Oxford University (UK). Mr Meng has published more than 50 papers in peer-reviewed journals including Gastroenterology, Gut, The American Journal of Human Genetics, and Journal of Thoracic Oncology, etc. His research area focused on the genetics of lung cancer in Chinese population. Mr Meng was one of the primary participants in the first genome-wide association study and exome-wide association study of lung cancer in Chinese population. He also help conducted the genome-wide association study of toxic and side effects of spinal cord and liver toxicity in platinum-based chemotherapy for lung cancer.

Siyan Zhan



Professor Zhan graduated from Beijing Medical University in 1986, now the Peking University Health Sciences Centre (PUHSC), and obtained postgraduate training in the Chinese University of Hong Kong. Her major is Epidemiology, especially pharmacoepidemiology. Prof. Zhan is the Director of the Center of Postmarketing Safety Evaluation, PUHSC, established in 2013. She is the member of IEA and ISPE, as well the Chairman of the Professional Committee of Pharmacoepidemiology of CPA and Vice Chairman of China Epidemiology Association. She is also the editor-in-chief of Chinese Journal of Pharmacoepidemiology and deputy editor-in-chief of Chinese Journal of Epidemiology. As a principal investigator, Prof. Zhan has already taken charge of many drug safety research projects supported by the national natural science foundation of China (NSFC), CFDA and global fund. She has published more than 100 papers in pharmcoepidemiology field and won many national prizes. In 2007, she has joined the translation of the famous Textbook of Pharmacoepidemiology (Brian L. Strom and Stephen E. Kimmel eds.) into Chinese. She is also the editor-in-chief, the current Textbook of Epidemiology, Textbook of Clinical Epidemiology and Textbook of Pharmacoepidemiology in China.

Wei Xu



Dr. Wei Xu is an Associate Professor at Dalla Lana School of Public Health, University of Toronto. He is heading the Biostatistics Department at the Princess Margaret Cancer Centre. Dr. Xu's research interests focus on statistical modeling, clinical trial design and methodology, statistical genetics, biomarker research, predictive model construction, and personalized medicine development. So far, he has been published over 260 peer-reviewed papers in high impact journals on statistics, bioinformatics, medical science, and human genetics. Dr. Xu is also a co-Director of the COMBIEL training program at Ontario Cancer Institute.